(Total Views: 636)
Posted On: 11/01/2022 8:08:17 AM
Post# of 148870
Cyrus struck a new tone in this past CC ...
This remark from Cyrus has only been mentioned once on the board, and even that citation was a misquote.
Just over a minute before the end of his remarks, Cyrus declared, "We believe that Leronlimab has the potential to become the standard of care in these indications in the future."
The indications he was talking about were solid-tumor cancer and NASH.
The whole thrust of this new management has been to say as little as possible in general, and especially tone down the rosy forward-looking remarks. But in this instance Cyrus was practically channeling Nader. He didn't hold up three fingers, no. But if CYDY still has a big stake in Leronlimab when it becomes the SOC for both solid-tumor cancer and NASH, Cyrus won't have to hold those fingers up. No: the three digits will be plain to see in, surely, the NASDAQ listings, under C.
This remark from Cyrus has only been mentioned once on the board, and even that citation was a misquote.
Just over a minute before the end of his remarks, Cyrus declared, "We believe that Leronlimab has the potential to become the standard of care in these indications in the future."
The indications he was talking about were solid-tumor cancer and NASH.
The whole thrust of this new management has been to say as little as possible in general, and especially tone down the rosy forward-looking remarks. But in this instance Cyrus was practically channeling Nader. He didn't hold up three fingers, no. But if CYDY still has a big stake in Leronlimab when it becomes the SOC for both solid-tumor cancer and NASH, Cyrus won't have to hold those fingers up. No: the three digits will be plain to see in, surely, the NASDAQ listings, under C.
(17)
(0)Scroll down for more posts ▼
